Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | HPGD | P15428 | 4/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | FABP4 | P15090 | 2/20 | 0.36 |
| ▸ | FABP3 | P05413 | 1/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.35 |
| ▸ | MASP2 | O00187 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | APAF1 | O14727 | 2/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | CASP6 | P55212 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14742691 | 0.74 | FBP1 (0.48) | — | |
| SCHEMBL29508765 | 0.74 | FBP1 (0.48) | — | |
| SCHEMBL769912 | 0.74 | FBP1 (0.48) | — | |
| SCHEMBL3290451 | 0.73 | SLC5A2 (0.53) | NPC1RAB9ACA1 | |
| Pyrophosphoric Acid SCHEMBL14742591 | 0.71 | FBP1 (0.45) | — | |
| SCHEMBL379657 | 0.68 | ADORA1 (0.41) | — | |
| SCHEMBL16098965 | 0.66 | RAB9A (0.38) | NPC1RAB9APOLBMAPTCA12 | |
| SCHEMBL7782835 | 0.63 | HPGD (0.39) | ALDH1A1HPGDHSD17B10KMT2AKDM4E | |
| Phosphoric Acid SCHEMBL20984773 | 0.62 | FABP4 (0.52) | DHODHALDH1A1HPGDHSD17B10FABP4 | |
| SCHEMBL24074130 | 0.61 | GRIK1 (0.58) | ALDH1A1HPGDHSD17B10FABP4FABP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092179-A1 | GENETICALLY MODIFIED HOST CELLS PRODUCING VIOLACEIN, ANALOGUES, AND DERIVATIVES THEREOF | OCTARINE BIO APS (DK) | 2026-04-02 | — | — | US | claimed |
| US-20240254533-A1 | METHODS FOR PRODUCING TRYPTAMINE DERIVATIVES | OCTARINE BIO APS (DK) | 2024-08-01 | — | — | US | claimed |
| EP-4347856-A2 | METHODS FOR PRODUCING TRYPTAMINE DERIVATIVES | Octarine Bio ApS (DK) | 2024-04-10 | — | — | EP | claimed |
| WO-2024068434-A2 | GENETICALLY MODIFIED HOST CELLS PRODUCING VIOLACEIN, ANALOGUES, AND DERIVATIVES THEREOF | OCTARINE BIO APS (DK) | 2024-04-04 | — | — | WO | claimed |
| WO-2022248635-A2 | METHODS FOR PRODUCING TRYPTAMINE DERIVATIVES. | OCTARINE BIO APS (DK) | 2022-12-01 | — | — | WO | claimed |
| US-20190032014-A1 | USING MICROBIOTA METABOLITES TO DIFFERENTIATE NAÏVE T-CELLS AND RELATED METHODS TO INDUCE OR PREVENT INFLAMMATORY CONDITIONS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2019-01-31 | — | — | US | claimed |
| EP-3430128-A1 | USING MICROBIOTA METABOLITES OT DIFFERENTIATE NAIVE T-CELLS AND RELATED METHODS TO INDUCE OR PREVENT INFLAMMATORY CONDITIONS | The Texas A&M University System (US) | 2019-01-23 | — | — | EP | claimed |
| WO-2017161268-A1 | USING MICROBIOTA METABOLITES OT DIFFERENTIATE NAIVE T-CELLS AND RELATED METHODS TO INDUCE OR PREVENT INFLAMMATORY CONDITIONS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2017-09-21 | — | — | WO | claimed |
| EP-4739326-A2 | PRODUCTION & SECRETION OF AUXIN-LIKE MOLECULES IN BACTERIA | SNIPR Biome ApS (DK) | 2026-05-13 | — | — | EP | disclosed |
| EP-4739777-A1 | TRANSMISSIBLE ELEMENTS COMPRISING PATHWAY MODIFICATION SYSTEMS AND EXOGENOUS NUCLEIC ACIDS FOR THE PRODUCTION OF MOLECULES OF INTEREST | SNIPR Biome ApS (DK) | 2026-05-13 | — | — | EP | disclosed |
| US-20260115234-A1 | PRODUCTION & SECRETION OF AUXIN-LIKE MOLECULES IN BACTERIA | SNIPR BIOME APS (DK) | 2026-04-30 | — | — | US | disclosed |
| US-20260092179-A1 | GENETICALLY MODIFIED HOST CELLS PRODUCING VIOLACEIN, ANALOGUES, AND DERIVATIVES THEREOF | OCTARINE BIO APS (DK) | 2026-04-02 | — | — | US | disclosed |
| WO-2025231196-A1 | MODIFIED BRUCELLA STRAINS AND METHODS OF USE FOR TREATMENT OF DISEASE | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2025-11-06 | — | — | WO | disclosed |
| US-20250179576-A1 | MICROBIAL SIGNATURES OF AUTISM SPECTRUM DISORDER | PITON THERAPEUTICS, INC. (US) | 2025-06-05 | — | — | US | disclosed |
| US-7751981-B2 | Articles of manufacture and methods for modeling Saccharomyces cerevisiae metabolism | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-07-06 | — | — | US | disclosed |
| US-20090259451-A1 | REVERSE ENGINEERING GENOME-SCALE METABOLIC NETWORK RECONSTRUCTIONS FOR ORGANISMS WITH INCOMPLETE GENOME ANNOTATION AND DEVELOPING CONSTRAINTS USING PROTON FLUX STATES AND NUMERICALLY-DETERMINED SUB-SYSTEMS | UNIVERSITY OF DELAWARE (US) | 2009-10-15 | — | — | US | disclosed |
| EP-0698218-B1 | LABELLED CARBOHYDRATES AND THEIR USE IN ASSAYS | OXFORD GLYCOSCIENCES UK LTD (GB) | 1999-10-27 | — | — | EP | disclosed |
| US-5747347-A | DISTINGUISHING BETWEEN CARBOHYDRATES IN MIXTURE BY LABELLING AT REDUCING TERMINAL WITH HYDROPHILIC FLUORESCENT MOIETY, SEPARATING BY DETECTING LABEL | OXFORD GLYCOSYSTEMS LTD. (GB) | 1998-05-05 | — | — | US | disclosed |
| EP-0698218-A1 | LABELLED CARBOHYDRATES AND THEIR USE IN ASSAYS | Oxford GlycoSciences (UK) Limited (GB) | 1996-02-28 | — | — | EP | disclosed |
| WO-1994028423-A1 | LABELLED CARBOHYDRATES AND THEIR USE IN ASSAYS | OXFORD GLYCOSYSTEMS LTD. (GB) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115234-A1 | PRODUCTION & SECRETION OF AUXIN-LIKE MOLECULES IN BACTERIA | AADAT, NAT1, IDO1 | DHODH 1311/4885ALDH1A1 123/4885HPGD 508/4885 |
| US-20260092179-A1 | GENETICALLY MODIFIED HOST CELLS PRODUCING VIOLACEIN, ANALOGUES, AND DERIVATIVES THEREOF | TDO2, BLVRB, INMT | DHODH 83/4885ALDH1A1 1612/4885HPGD 97/4885 |
| US-20190032014-A1 | USING MICROBIOTA METABOLITES TO DIFFERENTIATE NAÏVE T-CELLS AND RELATED METHODS TO INDUCE OR PREVENT INFLAMMATORY CONDITIONS | CD69, CD14, IL17A | DHODH 1410/4885ALDH1A1 599/4885HPGD 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.